Even Holth Rustad
@EHRustad
Followers
511
Following
587
Media
10
Statuses
574
Hematology fellow & immuno-oncology researcher @oslounivsykehus | Cell & gene therapy dev | Former @MSKCancerCenter myeloma | Learn, share, do no harm
Oslo, Norge
Joined March 2013
New preprint out today on @biorxivpreprint:"Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma"! Another study from our fantastic collaboration with @HDMyeloma @MSKCancerCenter @SylvesterCancer @univmiami @MayoClinic @MayoMyeloma #mmsm #wgs Twittorial 🧵1/21
2
15
50
SMM: Taking the narrow over the wide path https://t.co/jPBsZo5Dxv This is a plea (and not a criticism) to #msmm #myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM as MGUS or MM
1
12
28
Using excel to do calculations is like pipetting by mouth - convenient, usually fine, but sometimes you ingest an ectoparasite and lose $92 million
Norway’s $1.5 trillion sovereign wealth fund lost $92 million because of an excel spreadsheet error - "the most consequential misdated cell in history"?
13
128
909
Excited to see our new paper entitled "Genomic Classification and Individualized Prognosis in Multiple Myeloma" out on @JCO_ASCO! A fantastic collaboration between @SylvesterCancer, @univmiami, @MSKCancerCenter, @nyulangone, @MoffittNews, @HDMyeloma and many others!! #mmsm (1/x)
11
54
163
Targeted depletion of TRBV9+ T cells induces remission in a single ankylosing spondylitis patient, with significant improvements in functional and mobility metrics #Immunotherapy #AnkylosingSpondylitis
nature.com
Nature Medicine - Targeted depletion of TRBV9+ T cells induces remission in a single patient with ankylosing spondylitis, with significant improvements in functional and mobility metrics.
2
34
62
What #Tcells are hiding in your #SingleCell data? Plenty of existing tools that claim to address this challenge, but are they consistent? Our review is now out in @FrontImmunol , with thanks to @czi for funding! https://t.co/sa7akF93Mg
1
17
63
Foldvari et al. developed a pipeline to map TCR reactivity to the complete proteome to evaluate TCR candidates for clinical translation. https://t.co/WdNeSvQY3L @UniOslo_MED @ChariteBerlin @Jolweus #ImmunotherapyResearch
0
3
6
Congrats to brilliant postdoc Zsofia Fôldvari on her paper outlining a much-needed strategy to select safe T-cell receptors! https://t.co/8HJRLYkpBZ A wonderful collaboration with M. Leisegang and team at @ChariteBerlin & our team @UniOslo_MED / @Oslounivsykehus . @Nature_NPJ
1
6
31
Academics agreeing to exciting new papers & projects…
165
1K
10K
Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams. Happy to share our bench>bedside journey 1/10
42
133
579
Feasibility of clinical whole genome and transcriptome sequencing (WGTS) in oncology. A 🧵 on our latest study published in Nature Communications today: https://t.co/6007GkYDAc
7
77
248
Fulltreffer om tilgang til nye dyre medisiner - en utfordring for helsesystemet som vi MÅ løse sammen for pasientene @ingvildkjerkol @Bekkemellem @sigridbratlie @IngridSRoss @Kreftforeningen
nrk.no
Nordmenn får ikke den beste medisinske behandlingen fordi myndighetene somler.
0
1
4
New preprint from the lab!! @BenDiamondMD & @BachisioZic tracked the life-history of therapy-related myeloid neoplasms using chemotherapy #mutationalsignatures. Great collaboration @DrOlaLandgren @SylvesterCancer @MSKCancerCenter @nyulangone #mmsm #leusm
biorxiv.org
Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms[1][1], [2][2]. Pre-leukemic clones (i.e.,...
3
11
32
After a multi-year effort from so many brilliant people involved in this project, I am excited to share our work published today in @NatureBiotech. @JOlweus @Irenegr5 @Oslounivsykehus @UniOslo
nature.com
Nature Biotechnology - Engineered T cells kill leukemic cells with little off-target toxicity.
3
32
90
This is an incredible time to be an #mmsm researcher and the Myeloma Service @sloan_kettering is hiring! #MedTwitter peeps, please see the link ( https://t.co/O2GupC7qAU) for details and email me on usmanis@mskcc.org #CureMM @ASH_hematology @ASCO @ASTCT
2
21
70
With Misha Roshal @LisaRoth_MD we are excited to share our last preprint where we interrogated for the first time the whole-genome landscape of classic Hodgkin lymphoma (cHL) @sloankettering @WeillCornell @SylvesterCancer @univmiami #lysms
https://t.co/QvVR0vMIwA (1/16)
biorxiv.org
The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells within a classic Hodgkin lymphoma (cHL) biopsy limits the ability to study the genomics of cHL. To circumvent this, our group has...
2
7
22
Beslutningsforum må nå revurdere mange metoder som fikk nei fordi lenalidomid var for dyrt - hva skjer nå? Pasientene har ikke tid til å vente @MyelomaOslo
1
0
4
Fantastiske nyheter! Den høye prisen på lenalidomid har vært hinder for livreddende behandling av benmargskreft - nå er det fri konkurranse og prisen har falt > 90%
dagensmedisin.no
Sykehusinnkjøp HF har inngått ny avtale for virkestoffet lenalidomid som benyttes i behandling av benmargskreft. I anbudet ga åtte av ni tilbydere tilbud med over 90 prosent rabatt. Avtalen som er...
1
0
7
T-cells from many people recognize the same elements in SARS-CoV2. This is good news for future vaccines. Public T-cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles
biorxiv.org
T-cell epitopes with broad population coverage may form the basis for a new generation of SARS-CoV-2 vaccines. However, published studies on immunoprevalence are limited by small test cohorts, low...
1
3
12